Yaroslav Kulyaba

409 total citations
9 papers, 98 citations indexed

About

Yaroslav Kulyaba is a scholar working on Genetics, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Yaroslav Kulyaba has authored 9 papers receiving a total of 98 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Yaroslav Kulyaba's work include Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Acute Lymphoblastic Leukemia research (4 papers). Yaroslav Kulyaba is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Acute Lymphoblastic Leukemia research (4 papers). Yaroslav Kulyaba collaborates with scholars based in United Kingdom, United States and Ukraine. Yaroslav Kulyaba's co-authors include M Gorczyca, Steen Lisby, Ira Gupta, Iryna Kryachok, Sebastian Grosicki, Astrid McKeown, Govind Babu, Jerzy Z. Błoński, Wojciech Homenda and Tadeusz Robak and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Yaroslav Kulyaba

9 papers receiving 96 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yaroslav Kulyaba United Kingdom	6	74	70	37	28	19	9	98
Maneesh Tandon United Kingdom	8	77 1.0×	99 1.4×	35 0.9×	65 2.3×	23 1.2×	18	138
Lesley-Ann Sutton Sweden	4	92 1.2×	71 1.0×	50 1.4×	23 0.8×	7 0.4×	5	110
Yufu Lin China	3	50 0.7×	35 0.5×	28 0.8×	22 0.8×	6 0.3×	10	81
Austin I. Kim United States	7	120 1.6×	129 1.8×	50 1.4×	55 2.0×	29 1.5×	17	179
Wayne Rothbaum United States	6	64 0.9×	43 0.6×	17 0.5×	37 1.3×	15 0.8×	13	109
Timothy J. Triche United States	4	63 0.9×	43 0.6×	45 1.2×	12 0.4×	12 0.6×	4	107
Éric Durot France	6	65 0.9×	74 1.1×	22 0.6×	21 0.8×	9 0.5×	26	92
John M. Pagel United States	6	77 1.0×	70 1.0×	17 0.5×	25 0.9×	14 0.7×	20	96
Diego Cortese Sweden	2	81 1.1×	58 0.8×	37 1.0×	10 0.4×	12 0.6×	3	97
Elżbieta Iskierka‐Jazdzewska Poland	7	71 1.0×	84 1.2×	26 0.7×	36 1.3×	11 0.6×	25	110

Countries citing papers authored by Yaroslav Kulyaba

Since Specialization

Citations

This map shows the geographic impact of Yaroslav Kulyaba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yaroslav Kulyaba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yaroslav Kulyaba more than expected).

Fields of papers citing papers by Yaroslav Kulyaba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yaroslav Kulyaba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yaroslav Kulyaba. The network helps show where Yaroslav Kulyaba may publish in the future.

Co-authorship network of co-authors of Yaroslav Kulyaba

This figure shows the co-authorship network connecting the top 25 collaborators of Yaroslav Kulyaba. A scholar is included among the top collaborators of Yaroslav Kulyaba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yaroslav Kulyaba. Yaroslav Kulyaba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Hamilton, Erika, Yaroslav Kulyaba, Patrick Neven, et al.. (2024). 2MO Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial. ESMO Open. 9. 103012–103012. 2 indexed citations

Oliveira, Mafalda, Erika Hamilton, Yaroslav Kulyaba, et al.. (2023). Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.. Journal of Clinical Oncology. 41(16_suppl). 1066–1066. 11 indexed citations

Cho, Byoung Chul, Konstantin Penkov, Igor Bondarenko, et al.. (2019). Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC). Annals of Oncology. 30. v518–v519. 1 indexed citations

Österborg, Anders, Andrey Zaritskey, Sebastian Grosicki, et al.. (2016). Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 57(9). 2037–2046. 20 indexed citations

Robak, Tadeusz, Krzysztof Warzocha, Govind Babu, et al.. (2016). Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leukemia & lymphoma. 58(5). 1084–1093. 39 indexed citations

Robak, Tadeusz, Krzysztof Warzocha, Govind Babu, et al.. (2016). Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. Leukemia & lymphoma. 58(7). 1598–1606. 10 indexed citations

Robak, Tadeusz, Sebastian Grosicki, Krzysztof Warzocha, et al.. (2015). Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2. Haematologica. 100. 3 indexed citations

Robak, Tadeusz, Krzysztof Warzocha, K Govind Babu, et al.. (2015). Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial. Blood. 126(23). 5288–5288. 5 indexed citations

Österborg, Anders, Andrey Zaritskey, Per‐Ola Andersson, et al.. (2014). Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242. Blood. 124(21). 4684–4684. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact